Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
17
MBX.TO Quote, Financials, Valuation and Earnings
Last price:
$0.22
Seasonality move
:
30.41%
Day range:
$0.22 - $0.22
52-week range:
$0.21 - $0.55
Dividend yield:
0%
P/E ratio:
25.45x
P/S ratio:
1.61x
P/B ratio:
1.08x
Volume:
61.9K
Avg. volume:
57.4K
1-year change:
-41.89%
Market cap:
$29.9M
Revenue:
$18.6M
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MBX.TO
Microbix Biosystems, Inc.
|
$4.6M | -- | -35.34% | -- | $0.50 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MBX.TO
Microbix Biosystems, Inc.
|
$0.22 | $0.50 | $29.9M | 25.45x | $0.00 | 0% | 1.61x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $8.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MBX.TO
Microbix Biosystems, Inc.
|
19.6% | -1.182 | 18.23% | 4.95x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MBX.TO
Microbix Biosystems, Inc.
|
$1.5M | -$1.4M | -6.35% | -7.73% | -37.58% | -$70.3K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Microbix Biosystems, Inc. vs. Competitors
-
Which has Higher Returns MBX.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -39.55% compared to Microbix Biosystems, Inc.'s net margin of --. Microbix Biosystems, Inc.'s return on equity of -7.73% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBX.TOMicrobix Biosystems, Inc.40.53% -$0.01 $34.6M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About MBX.TO or COOL.CX?
Microbix Biosystems, Inc. has a consensus price target of $0.50, signalling upside risk potential of 132.56%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Microbix Biosystems, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Microbix Biosystems, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBX.TOMicrobix Biosystems, Inc.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is MBX.TO or COOL.CX More Risky?
Microbix Biosystems, Inc. has a beta of 0.504, which suggesting that the stock is 49.627% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock MBX.TO or COOL.CX?
Microbix Biosystems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbix Biosystems, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBX.TO or COOL.CX?
Microbix Biosystems, Inc. quarterly revenues are $3.7M, which are larger than Core One Labs, Inc. quarterly revenues of --. Microbix Biosystems, Inc.'s net income of -$1.5M is higher than Core One Labs, Inc.'s net income of --. Notably, Microbix Biosystems, Inc.'s price-to-earnings ratio is 25.45x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbix Biosystems, Inc. is 1.61x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBX.TOMicrobix Biosystems, Inc.1.61x 25.45x $3.7M -$1.5M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns MBX.TO or CURE.X.CX?
Biocure Technology has a net margin of -39.55% compared to Microbix Biosystems, Inc.'s net margin of --. Microbix Biosystems, Inc.'s return on equity of -7.73% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBX.TOMicrobix Biosystems, Inc.40.53% -$0.01 $34.6M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About MBX.TO or CURE.X.CX?
Microbix Biosystems, Inc. has a consensus price target of $0.50, signalling upside risk potential of 132.56%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Microbix Biosystems, Inc. has higher upside potential than Biocure Technology, analysts believe Microbix Biosystems, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings MBX.TOMicrobix Biosystems, Inc.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is MBX.TO or CURE.X.CX More Risky?
Microbix Biosystems, Inc. has a beta of 0.504, which suggesting that the stock is 49.627% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MBX.TO or CURE.X.CX?
Microbix Biosystems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbix Biosystems, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBX.TO or CURE.X.CX?
Microbix Biosystems, Inc. quarterly revenues are $3.7M, which are larger than Biocure Technology quarterly revenues of --. Microbix Biosystems, Inc.'s net income of -$1.5M is higher than Biocure Technology's net income of --. Notably, Microbix Biosystems, Inc.'s price-to-earnings ratio is 25.45x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbix Biosystems, Inc. is 1.61x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBX.TOMicrobix Biosystems, Inc.1.61x 25.45x $3.7M -$1.5M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns MBX.TO or HEAL.CX?
has a net margin of -39.55% compared to Microbix Biosystems, Inc.'s net margin of --. Microbix Biosystems, Inc.'s return on equity of -7.73% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBX.TOMicrobix Biosystems, Inc.40.53% -$0.01 $34.6M HEAL.CX-- -- -- -
What do Analysts Say About MBX.TO or HEAL.CX?
Microbix Biosystems, Inc. has a consensus price target of $0.50, signalling upside risk potential of 132.56%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Microbix Biosystems, Inc. has higher upside potential than , analysts believe Microbix Biosystems, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings MBX.TOMicrobix Biosystems, Inc.0 0 0 HEAL.CX0 0 0 -
Is MBX.TO or HEAL.CX More Risky?
Microbix Biosystems, Inc. has a beta of 0.504, which suggesting that the stock is 49.627% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MBX.TO or HEAL.CX?
Microbix Biosystems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbix Biosystems, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBX.TO or HEAL.CX?
Microbix Biosystems, Inc. quarterly revenues are $3.7M, which are larger than quarterly revenues of --. Microbix Biosystems, Inc.'s net income of -$1.5M is higher than 's net income of --. Notably, Microbix Biosystems, Inc.'s price-to-earnings ratio is 25.45x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbix Biosystems, Inc. is 1.61x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBX.TOMicrobix Biosystems, Inc.1.61x 25.45x $3.7M -$1.5M HEAL.CX-- -- -- --
-
Which has Higher Returns MBX.TO or LOBE.CX?
Lobe Sciences Ltd. has a net margin of -39.55% compared to Microbix Biosystems, Inc.'s net margin of --. Microbix Biosystems, Inc.'s return on equity of -7.73% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBX.TOMicrobix Biosystems, Inc.40.53% -$0.01 $34.6M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About MBX.TO or LOBE.CX?
Microbix Biosystems, Inc. has a consensus price target of $0.50, signalling upside risk potential of 132.56%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 15780.37%. Given that Lobe Sciences Ltd. has higher upside potential than Microbix Biosystems, Inc., analysts believe Lobe Sciences Ltd. is more attractive than Microbix Biosystems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBX.TOMicrobix Biosystems, Inc.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is MBX.TO or LOBE.CX More Risky?
Microbix Biosystems, Inc. has a beta of 0.504, which suggesting that the stock is 49.627% less volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock MBX.TO or LOBE.CX?
Microbix Biosystems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbix Biosystems, Inc. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBX.TO or LOBE.CX?
Microbix Biosystems, Inc. quarterly revenues are $3.7M, which are larger than Lobe Sciences Ltd. quarterly revenues of --. Microbix Biosystems, Inc.'s net income of -$1.5M is lower than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Microbix Biosystems, Inc.'s price-to-earnings ratio is 25.45x while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbix Biosystems, Inc. is 1.61x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBX.TOMicrobix Biosystems, Inc.1.61x 25.45x $3.7M -$1.5M LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns MBX.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -39.55% compared to Microbix Biosystems, Inc.'s net margin of --. Microbix Biosystems, Inc.'s return on equity of -7.73% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MBX.TOMicrobix Biosystems, Inc.40.53% -$0.01 $34.6M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About MBX.TO or NSHS.CX?
Microbix Biosystems, Inc. has a consensus price target of $0.50, signalling upside risk potential of 132.56%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Microbix Biosystems, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Microbix Biosystems, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MBX.TOMicrobix Biosystems, Inc.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is MBX.TO or NSHS.CX More Risky?
Microbix Biosystems, Inc. has a beta of 0.504, which suggesting that the stock is 49.627% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock MBX.TO or NSHS.CX?
Microbix Biosystems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbix Biosystems, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MBX.TO or NSHS.CX?
Microbix Biosystems, Inc. quarterly revenues are $3.7M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Microbix Biosystems, Inc.'s net income of -$1.5M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Microbix Biosystems, Inc.'s price-to-earnings ratio is 25.45x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbix Biosystems, Inc. is 1.61x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MBX.TOMicrobix Biosystems, Inc.1.61x 25.45x $3.7M -$1.5M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
